Gisadenafil

Drug Profile

Gisadenafil

Alternative Names: UK-369,003

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia; Chronic obstructive pulmonary disease; Erectile dysfunction; Overactive bladder

Most Recent Events

  • 27 Aug 2007 No development reported - Phase-I/II for Chronic obstructive pulmonary disease in Argentina (PO)
  • 27 Aug 2007 No development reported - Phase-I/II for Chronic obstructive pulmonary disease in Australia (PO)
  • 27 Aug 2007 No development reported - Phase-I/II for Chronic obstructive pulmonary disease in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top